Immunotherapy has shown remarkable successes in several tumor types and is now the first-line treatment for several conditions, including recurring disease. Nonetheless, a large fraction of patients does not respond, which is particularly true in glioblastoma. The results of Lee-Chang and colleagues point to intratumoral B cells as a potential target for immunotherapy.
ASJC Scopus subject areas
- Cancer Research